These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 18840134

  • 1. Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.
    Fujita Y, Hiramatsu M, Kawai M, Sumiyoshi K, Nishimura H, Tanigawa N.
    Dis Esophagus; 2008; 21(6):496-501. PubMed ID: 18840134
    [Abstract] [Full Text] [Related]

  • 2. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
    Kajiura S, Hosokawa A, Yoshita H, Ueda Y, Ueda A, Mihara H, Ando T, Fujinami H, Nishikawa J, Ogawa K, Minemura M, Sugiyama T.
    Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer.
    Kanekiyo S, Takeda S, Nakajima M, Nishiyama M, Kitahara M, Shindou Y, Michihisa I, Abe T, Yoshino S, Hazama S, Nagano H.
    Anticancer Res; 2016 Apr; 36(4):1923-7. PubMed ID: 27069181
    [Abstract] [Full Text] [Related]

  • 4. A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma.
    Akutsu Y, Shuto K, Kono T, Uesato M, Hoshino I, Shiratori T, Miyazawa Y, Isozaki Y, Akanuma N, Matsubara H.
    Hepatogastroenterology; 2012 Oct; 59(119):2095-8. PubMed ID: 22328303
    [Abstract] [Full Text] [Related]

  • 5. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
    Jin J, Xu X, Wang F, Yan G, Liu J, Lu W, Li X, Tucker SJ, Zhong B, Cao Z, Wang D.
    J Thorac Oncol; 2009 Aug; 4(8):1017-21. PubMed ID: 19542899
    [Abstract] [Full Text] [Related]

  • 6. A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
    Nakajima Y, Kawada K, Tokairin Y, Hoshino A, Okada T, Kawano T.
    Dig Surg; 2018 Aug; 35(2):131-137. PubMed ID: 28554183
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
    Shim HJ, Cho SH, Hwang JE, Bae WK, Song SY, Cho SB, Lee WS, Joo YE, Na KJ, Chung IJ.
    Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
    [Abstract] [Full Text] [Related]

  • 8. Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation.
    Yoshioka T, Sakayori M, Kato S, Chiba N, Miyazaki S, Nemoto K, Shibata H, Shimodaira H, Ohtsuka K, Kakudo Y, Sakata Y, Ishioka C.
    Int J Clin Oncol; 2006 Dec; 11(6):454-60. PubMed ID: 17180514
    [Abstract] [Full Text] [Related]

  • 9. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study.
    Ohnuma H, Sato Y, Hayasaka N, Matsuno T, Fujita C, Sato M, Osuga T, Hirakawa M, Miyanishi K, Sagawa T, Fujikawa K, Ohi M, Okagawa Y, Tsuji Y, Hirayama M, Ito T, Nobuoka T, Takemasa I, Kobune M, Kato J.
    Cancer Sci; 2018 Nov; 109(11):3554-3563. PubMed ID: 30137686
    [Abstract] [Full Text] [Related]

  • 10. Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting.
    Osaka Y, Takagi Y, Hoshino S, Tachibana S, Tsuchida A, Aoki T.
    Dis Esophagus; 2006 Nov; 19(6):473-6. PubMed ID: 17069591
    [Abstract] [Full Text] [Related]

  • 11. A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer.
    Nakajima Y, Suzuki T, Haruki S, Ogiya K, Kawada K, Nishikage T, Nagai K, Kawano T.
    Hepatogastroenterology; 2008 Nov; 55(86-87):1631-5. PubMed ID: 19102357
    [Abstract] [Full Text] [Related]

  • 12. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
    Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Kato T, Kitadani J, Tabata H, Takeuchi A, Iwahashi M, Yamaue H.
    Anticancer Res; 2016 Feb; 36(2):829-34. PubMed ID: 26851048
    [Abstract] [Full Text] [Related]

  • 13. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
    Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Matsumura S, Iwahashi M, Yamaue H.
    Dis Esophagus; 2017 Feb 01; 30(2):1-7. PubMed ID: 26725778
    [Abstract] [Full Text] [Related]

  • 14. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N, West Japan Oncology Group.
    Lancet Oncol; 2015 Dec 01; 16(16):1630-8. PubMed ID: 26522337
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
    Miyawaki Y, Nakajima Y, Kawada K, Okada T, Tokairin Y, Kawano T.
    Dis Esophagus; 2017 Feb 01; 30(2):1-8. PubMed ID: 27001629
    [Abstract] [Full Text] [Related]

  • 16. Utility of weekly docetaxel combined with preoperative radiotherapy for locally advanced esophageal cancer from pathological analysis.
    Kushida T, Nohara S, Yoshino K, Fujiwara D, Ouchi K, Amano T, Isayama F, Tomita N, Iwanuma Y, Sasai K, Tsurumaru M, Kajiyama Y.
    Dis Esophagus; 2014 Feb 01; 27(4):368-73. PubMed ID: 23865505
    [Abstract] [Full Text] [Related]

  • 17. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
    Tanaka T, Fujita H, Sueyoshi S, Tanaka Y, Sasahara H, Mori N, Nagano T, Yamana H, Shirouzu K.
    Chemotherapy; 2007 Feb 01; 53(6):449-53. PubMed ID: 17952006
    [Abstract] [Full Text] [Related]

  • 18. A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.
    Yamazaki K, Hironaka S, Boku N, Yasui H, Fukutomi A, Yoshino T, Onozawa Y, Hasuike N, Inui T, Yamaguchi Y, Ono H.
    Int J Clin Oncol; 2008 Apr 01; 13(2):150-5. PubMed ID: 18463960
    [Abstract] [Full Text] [Related]

  • 19. Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?
    Lyu X, Huang J, Mao Y, Liu Y, Feng Q, Shao K, Gao S, Jiang Y, Wang J, He J.
    J Surg Oncol; 2014 Dec 01; 110(7):864-8. PubMed ID: 24976079
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.
    Zhang F, Wang Y, Wang ZQ, Sun P, Wang DS, Jiang YX, Zhang DS, Wang FH, Xu RH, Li YH.
    Dis Esophagus; 2017 Feb 01; 30(2):1-8. PubMed ID: 27868295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.